Drugs / M3258
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04075721 | Sep 2019 → Apr 2021 | plasma cell myeloma | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M3258 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04075721 ↗ |
| Action | Inhibit | “M3258 is an orally bioavailable, potent, selective, reversible inhibitor of the large multifunctional peptidase 7 (LMP7, β5i, PSMB8) proteolytic subunit of the immunoproteasome” PMID 36273822 ↗ Oct 2022 |
| Route | Oral | “Participants received M3258 at a dose of 10 milligrams (mg) orally” NCT04075721 ↗ |
| Target | PSMB8 | “M3258 is an orally bioavailable, potent, selective, reversible inhibitor of the large multifunctional peptidase 7 (LMP7, β5i, PSMB8) proteolytic subunit of the immunoproteasome” PMID 36273822 ↗ Oct 2022 |